1. Home
  2. ALKT vs ODTX Comparison

ALKT vs ODTX Comparison

Compare ALKT & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alkami Technology Inc.

ALKT

Alkami Technology Inc.

N/A

Current Price

$12.63

Market Cap

1.4B

Sector

Technology

ML Signal

N/A

Logo Odyssey Therapeutics Inc. Common Stock

ODTX

Odyssey Therapeutics Inc. Common Stock

N/A

Current Price

$18.32

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ALKT
ODTX
Founded
2007
2021
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
2021
2025

Fundamental Metrics

Financial Performance
Metric
ALKT
ODTX
Price
$12.63
$18.32
Analyst Decision
Hold
Strong Buy
Analyst Count
9
8
Target Price
$16.17
★ $34.67
AVG Volume (30 Days)
★ 2.1M
272.0K
Earning Date
10-28-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $152,159,000.00
N/A
Revenue This Year
$19.72
N/A
Revenue Next Year
$14.10
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 35.68
N/A
52 Week Low
$12.10
$15.10
52 Week High
$24.47
$29.05

Technical Indicators

Market Signals
Indicator
ALKT
ODTX
Relative Strength Index (RSI) 36.18 42.69
Support Level $12.10 $15.73
Resistance Level $14.52 $19.60
Average True Range (ATR) 0.66 1.72
MACD -0.01 -0.06
Stochastic Oscillator 17.11 7.47

Price Performance

Historical Comparison
ALKT
ODTX

About ALKT Alkami Technology Inc.

Alkami Technology Inc is a cloud-based digital banking solutions provider. The company offers the Alkami Digital Sales & Service Platform, which includes a digital banking platform, onboarding and account opening solutions, and data and marketing tools. The platform enables financial institutions to onboard and engage users, support revenue growth, and improve operational efficiency through a cloud-based, multi-tenant architecture. The company provides services to clients under software-as-a-service arrangements. It derives substantially all of its revenues from SaaS subscription services charged for the use of digital sales and service solutions.

About ODTX Odyssey Therapeutics Inc. Common Stock

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.

Share on Social Networks: